Adjuvant hormone therapy (tamoxifen) is indicated for women with ER-positive tumours, and has been shown to decrease the risk of local recurrence and death.16–18 However, there is evidence from several studies that a beneficial effect of adjuvant hormone therapy is not observed in women with BRCA2-associated breast cancer. This evidence concerns the gene BRCA2 and breast carcinoma.